Trump announces trade deal with EU following months of negotiations
Anteris Technologies Global Corp. (NASDAQ:AVR) has announced changes to its board of directors, as detailed in a recent SEC filing. On June 7, the company appointed Gregory Moss and David Roberts to its board. Moss will serve as a Class I Director with his term ending at the 2025 annual stockholders meeting, while Roberts will serve as a Class III Director until the 2027 meeting. Moss will join the Nominating and Corporate Governance Committee, and Roberts will serve on the Audit and Risk Committee and the Compensation Committee.
Gregory Moss, 41, is currently the Chief Business and Legal Officer at Evommune, Inc. He has previously held senior roles at Kadmon, a Sanofi (NASDAQ:SNY) company, and has extensive legal and compliance experience. Moss also serves on the board of Vitls, Inc. David Roberts, 61, is the President of LeMaitre Vascular, Inc. (NASDAQ:LMAT) and has been with the company since 1997. His prior experience includes roles at BUCA, Inc. and HarbourVest Partners.
Both Moss and Roberts will receive compensation as non-employee directors, including an initial equity grant of restricted stock units valued at $250,000, subject to stockholder approval. They will also receive annual cash retainers and a prorated annual grant of RSUs.
In a related development, Dr. Wenyi Gu resigned from the board on June 5. His resignation was not due to any disagreement with the company. The board expressed gratitude for his contributions.
This information is based on a press release statement from Anteris Technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.